Sun Pharma Advanced Research Company Ltd is Rated Strong Sell

Understanding the Current Rating

The Strong Sell rating assigned to Sun Pharma Advanced Research Company Ltd indicates a cautious stance for investors, signalling significant concerns about the company’s fundamentals, valuation, financial trends, and technical outlook. This rating suggests that the stock is expected to underperform relative to the broader market and peers in the Pharmaceuticals & Biotechnology sector. Investors should carefully consider these factors before making investment decisions.

Quality Assessment

As of 10 January 2026, the company’s quality grade remains below average. A key concern is the negative book value, which points to weak long-term fundamental strength. Over the past five years, the company’s net sales have declined at an annualised rate of -24.65%, while operating profit has stagnated at 0%. This lack of growth undermines confidence in the company’s ability to generate sustainable earnings. Additionally, the company’s ability to service its debt is notably weak, with an average EBIT to interest ratio of -141.22, indicating that operating earnings are insufficient to cover interest expenses. This financial strain raises questions about the company’s operational efficiency and risk profile.

Valuation Considerations

The valuation grade for Sun Pharma Advanced Research Company Ltd is classified as risky. Despite the stock’s negative returns, the latest data shows a negative EBITDA, which is a red flag for investors assessing profitability and cash flow generation. The stock’s current valuation metrics suggest it is trading at levels that do not justify the underlying financial health, making it a speculative proposition. Over the past year, the stock has delivered a return of -30.03%, significantly underperforming the BSE500 benchmark, which has generated a positive return of 6.14% over the same period. This divergence highlights the market’s lack of confidence in the company’s prospects.

Financial Trend Analysis

The financial trend for the company is very negative. The latest quarterly results reveal a 6.73% decline in operating profit, with the company reporting negative results for two consecutive quarters. The net sales for the most recent quarter stand at a low ₹7.86 crores, while interest expenses have surged to ₹7.52 crores, further pressuring profitability. The company’s profit after tax (PAT) for the latest six months is a loss of ₹127.72 crores, reflecting a steep decline of 41.02%. These figures underscore the deteriorating financial health and raise concerns about the company’s ability to return to profitability in the near term.

Technical Outlook

Technically, the stock is mildly bearish. The recent price movement shows a 2.00% decline in a single day and a 6.69% drop over the past month. Although there was a modest 3.36% gain over three months, the six-month trend remains negative with a 16.28% decline. Year-to-date, the stock has fallen by 1.49%. These trends suggest that investor sentiment remains subdued, and the stock faces resistance in regaining upward momentum. The technical indicators align with the fundamental concerns, reinforcing the cautious stance.

Market Performance Context

Sun Pharma Advanced Research Company Ltd’s underperformance relative to the broader market is stark. While the BSE500 index has delivered a 6.14% return over the past year, the company’s stock has declined by 30.03%. This significant gap highlights the challenges the company faces in regaining investor confidence and market share. The combination of weak fundamentals, risky valuation, negative financial trends, and bearish technical signals contribute to the current Strong Sell rating.

What This Rating Means for Investors

For investors, the Strong Sell rating serves as a clear cautionary signal. It suggests that the stock is expected to continue facing headwinds and may not be suitable for those seeking capital appreciation or stable returns in the near to medium term. The rating reflects a comprehensive assessment of the company’s current financial health, market valuation, and technical position. Investors should weigh these factors carefully and consider alternative opportunities within the Pharmaceuticals & Biotechnology sector or broader market that offer stronger fundamentals and more favourable risk-reward profiles.

Summary of Key Metrics as of 10 January 2026

• Market Capitalisation: Smallcap segment

• Mojo Score: 6.0 (Strong Sell)

• Quality Grade: Below Average

• Valuation Grade: Risky

• Financial Grade: Very Negative

• Technical Grade: Mildly Bearish

• 1 Year Stock Return: -30.03%

• BSE500 1 Year Return Benchmark: +6.14%

Conclusion

Sun Pharma Advanced Research Company Ltd’s current Strong Sell rating by MarketsMOJO is grounded in a thorough evaluation of its deteriorating fundamentals, risky valuation, negative financial trends, and subdued technical indicators. While the rating was last updated on 01 Feb 2024, the analysis presented here is based on the latest data as of 10 January 2026, ensuring investors have an up-to-date perspective. Given the company’s ongoing challenges and underperformance relative to the market, investors are advised to approach this stock with caution and consider more robust alternatives for their portfolios.

Unlock special upgrade rates for a limited period. Start Saving Now →